Fibroblast growth factor-23 and risk of cardiovascular diseases: a Mendelian randomization study

Fibroblast growth factor-23 and risk of cardiovascular diseases: a Mendelian randomization study

<p><strong>Background:</strong> Fibroblast growth factor 23 (FGF-23) is associated with a range of cardiovascular and non-cardiovascular diseases in conventional epidemiological studies, but substantial residual confounding may exist. Mendelian randomization approaches can help con...

Podrobná bibliografie
Hlavní autoři:	Donovan, K, Herrington, W, Haynes, R, Sardell, R, Baigent, C, Holmes, M, Staplin, N
Médium:	Journal article
Jazyk:	English
Vydáno:	American Society of Nephrology 2022

Podobné jednotky

Fibroblast growth factor-23 and risks of cardiovascular and non-cardiovascular diseases: a meta-analysis
Autor: Marthi, A, a další
Vydáno: (2018)

Apolipoprotein B, triglyceride-rich lipoproteins, and risk of cardiovascular events in persons with CKD
Autor: Lamprea-Montealegre, J, a další
Vydáno: (2019)

Genetically Predicted Fibroblast Growth Factor 23 and Major Cardiovascular Diseases, Their Risk Factors, Kidney Function, and Longevity: A Two-Sample Mendelian Randomization Study
Autor: Ying Liang, a další
Vydáno: (2021-07-01)

Corrigendum: Genetically Predicted Fibroblast Growth Factor 23 and Major Cardiovascular Diseases, Their Risk Factors, Kidney Function, and Longevity: A Two-Sample Mendelian Randomization Study
Autor: Ying Liang, a další
Vydáno: (2021-11-01)

Fibroblast Growth Factor 23 and Cardiovascular Risk in Diabetes Patients—Cardiologists Be Aware
Autor: Anna Kurpas, a další
Vydáno: (2022-05-01)

Is fibroblast growth factor 23 a new cardiovascular risk marker in gestational diabetes?
Autor: Muhammed Kizilgul, a další
Vydáno: (2017-09-01)

Il Fibroblast Growth Factor-23 (FGF-23)
Autor: D. Rendina, a další
Vydáno: (2018-01-01)

Lowering LDL cholesterol reduces cardiovascular risk independently of presence of inflammation
Autor: Storey, B, a další
Vydáno: (2017)

Fibroblast Growth Factor 23 and Incident Cardiovascular Disease and Mortality in Middle‐Aged Adults
Autor: Shejuti Paul, a další
Vydáno: (2021-08-01)

Evidence for the prevention and treatment of stroke in dialysis patients
Autor: Herrington, W, a další
Vydáno: (2014)

Fibroblast growth factor 23 and calcium‐phosphate metabolism in relation to cardiovascular risk factors in patients with type 1 diabetes
Autor: Stephanie Vermeulen, a další
Vydáno: (2024-06-01)

Serum galectin-3 and fibroblast growth factor-23 levels in relation with type 2 diabetes and cardiovascular risk
Autor: Klisic Aleksandra, a další
Vydáno: (2025-01-01)

Osteoprotegerin and fibroblast growth factor 23 in the development of cardiovascular events in chronic kidney disease
Autor: F U Dzgoeva, a další
Vydáno: (2014-06-01)

Physiological Actions of Fibroblast Growth Factor-23
Autor: Reinhold G. Erben
Vydáno: (2018-05-01)

Frailty, multimorbidity and polypharmacy: exploratory analyses of the effects of empagliflozin from the EMPA-KIDNEY trial
Autor: Mayne, KM, a další
Vydáno: (2024)

Empagliflozin lowers serum uric acid in chronic kidney disease: exploratory analyses from the EMPA-KIDNEY trial
Autor: Mayne, K, a další
Vydáno: (2024)

Kidney disease trials for the 21st century: innovations in design and conduct
Autor: Herrington, W, a další
Vydáno: (2019)

PKC regulates the production of fibroblast growth factor 23 (FGF23).
Autor: Ludmilla Bär, a další
Vydáno: (2019-01-01)

Fibroblast Growth Factor-23 (FGF-23) e Sindrome Cardiorenale
Autor: Luca Di Lullo, a další
Vydáno: (2015-03-01)

A Case of Hyperphosphatemia and Elevated Fibroblast Growth Factor 23: A Brief Review of Hyperphosphatemia and Fibroblast Growth Factor 23 Pathway
Autor: Joseph Wang, a další
Vydáno: (2017-11-01)

The impact of growth differentiation factor 15 on the risk of cardiovascular diseases: two-sample Mendelian randomization study
Autor: Zhuo Wang, a další
Vydáno: (2020-10-01)

Evidence for reverse causality in the association between blood pressure and cardiovascular risk in patients with chronic kidney disease
Autor: Herrington, W, a další
Vydáno: (2016)

Role of Fibroblast Growth Factor 23 (FGF23) and αKlotho in Cancer
Autor: Franz Ewendt, a další
Vydáno: (2021-01-01)

The association of fibroblast growth factor 23 at mid-life and late-life with subsequent risk of cardiovascular disease: The Atherosclerosis Risk in Communities (ARIC) Study
Autor: Yasuyuki Honda, a další
Vydáno: (2022-01-01)

Campath, calcineurin inhibitor reduction and chronic allograft nephropathy (the 3C Study) – results of a randomized controlled clinical trial
Autor: Haynes, R, a další
Vydáno: (2018)

Conventional and genetic evidence on the association between adiposity and chronic kidney disease
Autor: Zhu, P, a další
Vydáno: (2020)

Causal Associations of Urate With Cardiovascular Risk Factors: Two-Sample Mendelian Randomization
Autor: Thitiya Lukkunaprasit, a další
Vydáno: (2021-07-01)

Role of fibroblast growth factor 23 in the development of cardiovascular diseases in patients with end-stage renal failure on programmed hemodialysis
Autor: F U Dzgoeva, a další
Vydáno: (2016-12-01)

Higher Fibroblast Growth Factor 23 Levels Are Causally Associated With Lower Bone Mineral Density of Heel and Femoral Neck: Evidence From Two-Sample Mendelian Randomization Analysis
Autor: Yue Wang, a další
Vydáno: (2020-09-01)

Fibroblast growth factor-23 and the risk of cardiovascular diseases and mortality in the general population: A systematic review and dose-response meta-analysis
Autor: Menglu Liu, a další
Vydáno: (2022-11-01)

Fibroblast growth factor-23 rs7955866 polymorphism and risk of chronic kidney disease
Autor: Yaser Aly Ammar, a další
Vydáno: (2022-04-01)

Mendelian randomization study of the relevance of blood pressure to vascular mortality among 150,000 participants in the Mexico City Prospective Study
Autor: Turner, M, a další
Vydáno: (2023)

Fibroblast growth factor 23 levels before and after renal transplantation
Autor: Mohamed M El-khatib, a další
Vydáno: (2016-01-01)

Relationship of Fibroblast Growth Factor 23 With Hospitalization for Heart Failure and Cardiovascular Outcomes in Patients Undergoing Cardiac Surgery
Autor: Felix Hofer, a další
Vydáno: (2023-03-01)

Fibroblast growth factor-23 and cardiovascular disease among prevalent hemodialysis patients focusing on residual kidney function
Autor: Youn Kyung Kee, a další
Vydáno: (2023-07-01)

Plasma Fibroblast Growth Factor 23: Clinical Correlates and Association With Cardiovascular Disease and Mortality in the Framingham Heart Study
Autor: Robin Haring, a další
Vydáno: (2016-07-01)

Fibroblast Growth Factor-23 Helps Explain the Biphasic Cardiovascular Effects of Vitamin D in Chronic Kidney Disease
Autor: Peng Hu, Qiang Xuan, Bo Hu, Ling Lu, Jing Wang, Yuan Han Qin
Vydáno: (2012-01-01)

Prognostic Importance of Fibroblast Growth Factor-23 in Dialysis Patients
Autor: Nilgül Akalin, a další
Vydáno: (2014-01-01)

Direct and indirect effects of fibroblast growth factor 23 on the heart
Autor: Toshiaki Nakano, a další
Vydáno: (2023-02-01)

Fibroblast Growth Factor-23—A Potential Uremic Toxin
Autor: Piotr Kuczera, a další
Vydáno: (2016-12-01)